Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992041 | 0.88 | KDM4E (0.30) | KDM4EALDH1A1PKM | |
| SCHEMBL7980542 | 0.87 | — | — | |
| SCHEMBL7992414 | 0.83 | — | — | |
| SCHEMBL11456470 | 0.83 | KDM4E (0.36) | KDM4EALDH1A1PKMTDP1HSD17B10 | |
| SCHEMBL2690835 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1PKMTDP1HSD17B10 | |
| SCHEMBL2145456 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1PKMTDP1HSD17B10 | |
| Acetic Acid SCHEMBL16498836 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1PKMTDP1HSD17B10 | |
| SCHEMBL22587458 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1PKMTDP1HSD17B10 | |
| SCHEMBL92858 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1PKMTDP1HSD17B10 | |
| SCHEMBL11571280 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1PKMTDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288340-B1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2416650-B1 | NANOPARTICLE FORMULATIONS AND USES THEROF | ABRAXIS BIOSCIENCE LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570431-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180363018-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Heterocyclic Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-20180289620-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2018-10-11 | — | — | US | disclosed |
| US-10087478-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a nitrogen-containing compound and uses thereof | NOVOZYMES, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-10041101-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2603594-B1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A BICYCLIC COMPOUND AND USES THEREOF | NOVOZYMES INC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2603598-B1 | COMPOSITIONS COMPRISING A GH61 POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A QUINONE COMPOUND AND USES THEREOF | NOVOZYMES INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC | 2009-10-22 | — | — | US | disclosed |
| WO-2009126938-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABRAXIS BIOSCIENCES, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126401-A1 | COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126175-A1 | COMPOSITIONS OF HYDROPHOBIC TAXANE DERIVATIVES AND USES THEREOF | ABRAXIS BIOSCIENCE, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
| US-6277790-B1 | APPLYING PLANTS, SEEDS, SOILS OR ENVIRONMENT | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-21 | — | — | US | disclosed |
| EP-1003741-A1 | SUBSTITUTED HERBICIDE TETRAZOLINONECARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007702-A1 | SUBSTITUTED HERBICIDE TETRAZOLINONECARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | PGLS, CEL, PNLIP | KDM4E 3424/4885ALDH1A1 3681/4885PKM 2194/4885 |
| US-20090263483-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | KDM4E 4658/4885ALDH1A1 1501/4885PKM 3884/4885 |
| US-20180289620-A1 | NANOPARTICLE FORMULATIONS AND USES THEREOF | ABCB1, SLC47A1, ABCC1 | KDM4E 4658/4885ALDH1A1 1501/4885PKM 3884/4885 |
| US-10570431-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | CEL, VIP, CTRC | KDM4E 3524/4885ALDH1A1 4339/4885PKM 1703/4885 |
| US-20180363018-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Heterocyclic Compound And Uses Thereof | CEL, VIP, CTRC | KDM4E 3524/4885ALDH1A1 4339/4885PKM 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.